Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(…

Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(… | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.

Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(…

News October 8, 2014

NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned ...